Walmark Further Expands Its Portfolio by Acquiring Pneumolan from Novascon Pharmaceuticals

June 2, 2015
Image 4 - blue

Walmark a.s. (“Walmark” or the “Company”), a major Consumer Healthcare player in Central and Eastern Europe with a leading position in dietary supplements, jointly controlled by MidEuropa and the founding Walach family announced today that it has further expanded its product portfolio in Poland by acquiring a range of products marketed under the Pneumolan brand (“Pneumolan”) from Novascon Pharmaceuticals.

Pneumolan is the leading children’s natural respiratory health brand in Poland and Walmark thereby becomes the leader in the natural products supporting the respiratory system category in the country.


Jorge Manuel, the CEO of Walmark commented:

“We are delighted to add Pneumolan to our product portfolio, which complements our existing presence in the attractive natural respiratory health category and further strengthens our position in the key Polish market.”


Michelle Capiod, Partner at MidEuropa added:

“The acquisition of Pneumolan represents another milestone in our buy-and-build strategy for Walmark. With MidEuropa’s support, the Company is currently pursuing several M&A initiatives across the markets of Central and Eastern Europe”.


Walmark was advised by Vienna Capital Partners, Pharmabroker, Baker & McKenzie and EY. Jan Krzewinski and Martin Zita supported Walmark’s management in executing the transaction.